This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008;87:43–8. https://doi.org/10.1007/s00277-007-0360-0
Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res. 2011;35:183–7. https://doi.org/10.1016/j.leukres.2010.07.016
Jo JC, Yoon DH, Kim S, Park JS, Park CS, Huh J, et al. Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma. Korean J Hematol. 2012;47:119–25. https://doi.org/10.5045/kjh.2012.47.2.119
Shin HJ, Lee WS, Lee HS, Kim H, Lee GW, Song MK, et al. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:2490–6. https://doi.org/10.3109/10428194.2014.882504
Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588–95. https://doi.org/10.1200/jco.1995.13.3.588
Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462–9. https://doi.org/10.1200/jco.2012.41.9416
Spina FDL, Dalto S. Long-term outcomes of autologous stem cell transplantation with BEAM conditioning in relapsed non-Hodgkin lymphoma: survival and late toxicities. EBMT Annual Meeting: Istanbul; 2015.
Rodriguez J, Caballero MD, Gutierrez A, Solano C, Arranz R, Lahuerta JJ, et al. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol. 2004;15:1504–9. https://doi.org/10.1093/annonc/mdh391
Isidori A, Christofides A, Visani G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma. 2016;57:2499–509. https://doi.org/10.1080/10428194.2016.1185785
d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9. https://doi.org/10.1200/jco.2011.40.2719
Kim JW, Lee HJ, Yi HG, Kim BS, Bang SM, Kim JS, et al. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am J Hematol. 2012;87:479–83. https://doi.org/10.1002/ajh.23150
Isidori A, Guidi S, Scalzulli PR, Olivieri A, Angelucci E, Capria S, et al. Benda-BEAM high-dose therapy prior to auto-SCT is effective in resistant/relapsed DLBCL. Blood. 2015;126:1999. https://doi.org/10.1182/blood.V126.23.1999.1999
Acknowledgements
This study received research funds from Korea Otsuka.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jo, JC., Kim, J.S., Lee, JH. et al. Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). Bone Marrow Transplant 55, 1466–1468 (2020). https://doi.org/10.1038/s41409-020-0908-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0908-3
This article is cited by
-
Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry
Bone Marrow Transplantation (2024)
-
Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas
Annals of Hematology (2021)